CD37 Recombinant Monoclonal Antibody

Code: CSB-RA004928MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, IHC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P11049

Target Names

CD37

Alternative Names

CD 37 antibody; CD37 antibody; CD37 antigen antibody; CD37 molecule antibody; CD37_HUMAN antibody; Cell differentiation antigen 37 antibody; GP52 40 antibody; Leukocyte antigen CD37 antibody; Leukocyte surface antigen CD37 antibody; MGC120234 antibody; Tetraspanin 26 antibody; Tetraspanin-26 antibody; Tetraspanin26 antibody; TSPAN 26 antibody; Tspan-26 antibody; TSPAN26 antibody

Species Reactivity

Human

Immunogen

Recombinant Human CD37 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

9H6

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Tested Applications

ELISA, IHC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200

Protocols

ELISA Protocol Immunohistochemistry (IHC) Protocol

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

IHC image of CSB-RA004928MA1HU diluted at 1:200 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-human polymer IgG labeled by HRP and visualized using 0.05% DAB.

Description

CD37 is a tetraspanin family member predominantly expressed on mature B cells, where it plays essential roles in B cell development, survival signaling, and immune cell interactions. This surface glycoprotein has emerged as a compelling target in hematological malignancy research, particularly in B cell lymphomas and chronic lymphocytic leukemia, making reliable detection tools invaluable for both basic immunology studies and translational research.

This recombinant monoclonal antibody, clone 9H6, offers the consistency and reproducibility that demanding research applications require. Generated against recombinant human CD37 protein and produced using recombinant technology, this antibody provides sequence-defined specificity with minimal lot-to-lot variation. The human IgG1 isotype format and affinity chromatography purification ensure high purity suitable for sensitive detection methods.

Validation in immunohistochemistry demonstrates reliable performance in formalin-fixed, paraffin-embedded human tissues. Testing in human tonsil tissue, a lymphoid organ rich in B cells, confirms specific staining at dilutions of 1:50 to 1:200 using citrate buffer antigen retrieval. The validation protocol employed a Leica Bond system with goat anti-human polymer detection, providing researchers with a well-characterized starting point for their own optimization.

Beyond immunohistochemistry, this antibody is also suitable for ELISA applications, offering flexibility across different experimental workflows. Whether investigating B cell biology, characterizing lymphoid tissue architecture, or exploring CD37 as a therapeutic target, this recombinant antibody delivers the reproducibility essential for generating publication-quality data in immunology and oncology research.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Gene References into Functions

CD37 is a critical determinant of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone outcome in diffuse large B-cell lymphoma. PMID:27760757
Data indicate that cell differentiation antigen 37 (CD37) is well expressed and a potential drug target in acute myeloid leukemia (AML). PMID:25934707
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. PMID:24445867
Data indicate that enhanced antibody-dependent cell cytotoxicity (ADCC) is observed against chronic lymphocytic leukemia cells and is sustained at concentrations of SMIP-016(GV) as low at 5E(-6) microg/mL on cells expressing minimal CD37 antigen. PMID:23883821
Identify two tyrosine residues in tetraspanin CD37 directly mediating transduction of survival and apoptotic signals. PMID:22624718
In the absence of both CD37 and Tssc6, immune function is further altered when compared with CD37- or Tssc6-deficient transgenic mice, demonstrating a complementary role for these two molecules in cellular immunity. PMID:20709950
CD37 cross-linking on human T cells transduces signals that lead to complete inhibition of CD3-induced T cell proliferation. PMID:14978098
CD37 is important for dectin-1 stabilization in APC membranes and controls dectin-1-mediated IL-6 production. PMID:17182550
provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies PMID:17440052